Chimeric Antigen Receptor (car) T Cell Therapy - Pharma

Relevant Publications

Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA reporting system.

Issue Release: 2024

Clinical and Genomic Profile of Primary Cranial Neurolymphomatosis.

Issue Release: 2024

Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.

Issue Release: 2024

Steering the course of CAR T cell therapy with lipid nanoparticles.

Issue Release: 2024

CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up.

Issue Release: 2024

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma.

Issue Release: 2024

Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide.

Issue Release: 2024

Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India.

Issue Release: 2024

Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma.

Issue Release: 2024

Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.

Issue Release: 2024

Matching-adjusted indirect comparisons of axicabtagene ciloleucel to mosunetuzumab for the treatment of relapsed/refractory follicular lymphoma.

Issue Release: 2024

Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review.

Issue Release: 2024

The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma.

Issue Release: 2024

Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients.

Issue Release: 2024

Expression of VISTA regulated via IFN-γ governs endogenous T-cell function and exhibits correlation with the efficacy of CD19 CAR-T cell treated B-malignant mice.

Issue Release: 2024

Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells.

Issue Release: 2024

Generation and Functional Verification of Hypoxia-sensitive Chimeric Antigen Receptor-T Cells.

Issue Release: 2024

Anaplastic Multiple Myeloma With a Novel Proliferation of Pleomorphic Binuclear Plasma Cells.

Issue Release: 2024

Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms.

Issue Release: 2024

CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives.

Issue Release: 2024

Why do Pharma Companies Use CROs?

How Can Pharma Companies Improve Patient Education?

What is Regulatory Approval?

What is Cellular Stress?

What Are Clinical Trials?

What Challenges Do Pharmacists Face?

What are Collaborative Care Models?

Why is Transitional Care Important in Pharma?

How Can Pharmacists Contribute to Transitional Care?

What Role Do Pharmacists Play in Patient Education?

Partnered Content Networks

Relevant Topics